Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial

類似資料

• Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial
  著者:: Folegatti, PM, 等
  出版事項: (2020)
• A single dose of ChAdOx1 Chik vaccine induces neutralising antibodies against four chikungunya virus lineages in a phase 1 clinical trial
  著者:: Folegatti, P, 等
  出版事項: (2021)
• A three-antigen Plasmodium falciparum DNA prime—Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults
  著者:: Sklar, MJ, 等
  出版事項: (2021)
• Safety and immunogenicity of adenovirus and poxvirus vectored vaccines against a Mycobacterium avium complex subspecies
  著者:: Folegatti, P, 等
  出版事項: (2021)
• Deep immune phenotyping and single-cell transcriptomics allow identification of circulating TRM-like cells which correlate with liver-stage immunity and vaccine-induced protection from malaria
  著者:: Noe, A, 等
  出版事項: (2022)